GALWAY, IRELAND--August 28, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Danish pharma major Novo Nordisk A/S (NYSE:NVO) (Bagsværd, Denmark) has announced plans to spend 1.5 billion Danish kroner (US$220 million) to build a new raw materials plant in Denmark to help meet significantly higher demand for the production of medicines to fight chronic diseases.

Within this article: Details investment in raw materials plant in Køge, Denmark, to support huge demand for its insulin and GLP-1 therapies, such as weight-loss treatment Wegovy and diabetes drug Ozempic, timeline, related investments.